The persistent mystery of respiratory illness without identified pathogens may be partially solved through deeper molecular investigation. When standard diagnostic tests return negative results, patients and clinicians are left without clear answers about the underlying cause of symptoms, potentially affecting treatment decisions and public health surveillance accuracy.
Researchers applied untargeted metagenomic sequencing to 305 respiratory samples that tested negative on BioFire multiplex panels and SARS-CoV-2 PCR assays. This comprehensive genetic approach detected previously missed viral pathogens in 16 samples, representing 5% of the negative cohort. The identified viruses included Influenza C, Human Bocavirus, Rhinovirus A and C variants, and even SARS-CoV-2 cases that standard testing had failed to capture. Complete viral genomes were successfully reconstructed for 14 specimens with over 90% coverage, enabling detailed strain analysis that revealed geographically clustered Bocavirus variants and diverse Rhinovirus lineages.
This diagnostic gap represents a significant blind spot in respiratory surveillance systems that rely heavily on targeted PCR-based platforms. While 5% detection improvement may seem modest, it translates to thousands of missed cases in large healthcare systems. The ability to recover complete genomes also provides crucial epidemiological intelligence for tracking variant emergence and transmission patterns. However, the clinical significance of some detected viruses, particularly at low levels, remains uncertain. Cost and turnaround time currently limit metagenomic approaches to research settings, though advancing technology may eventually make this comprehensive pathogen detection more accessible for routine clinical use.